Literature DB >> 8838783

A review of the treatment of primary headaches. Part I: Migraine.

M Leone1, L Grazzi, D D'Amico, F Moschiano, G Bussone.   

Abstract

Finding the best treatment for a patient's migraine is often a problem in clinical practice since the condition is very common, often debilitating and may prove refractory to therapy. Over recent years, more effective migraine treatments have been found and validated, and the traditional remedies have undergone controlled testing. This article reviews the various therapies available for both the acute treatment and prevention of migraine. Treatments often effective against migraine attacks are: aspirin, analgesics, non steroid anti-inflammatory drugs (NSAIDs), ergot derivatives and sumatriptan. Five main classes of prophylactic drug are currently used: beta-blockers, calcium antagonists, serotonin modulators, NSAIDs and ergot compounds. Biofeedback, one of the most efficacious non-pharmacological preventive treatments of migraine, is also discussed. The variables influencing the choice of acute and preventive treatments, including contraindications and drug availability, are also described in order to provide a practical and up-to-date guide to migraine therapy.

Entities:  

Mesh:

Year:  1995        PMID: 8838783     DOI: 10.1007/bf02230907

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  47 in total

1.  Prophylactic and therapeutic properties of 1-methyl-lysergic acid butanolamide in migraine.

Authors:  F SICUTERI
Journal:  Int Arch Allergy Appl Immunol       Date:  1959

2.  Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo.

Authors:  R Hering; A Kuritzky
Journal:  Cephalalgia       Date:  1992-04       Impact factor: 6.292

3.  Comparison of the calcium entry blockers nimodipine and flunarizine on human cerebral and temporal arteries: role in cerebrovascular disorders.

Authors:  I Jansen; P Tfelt-Hansen; L Edvinsson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study.

Authors:  P Tfelt-Hansen; J Olesen
Journal:  Cephalalgia       Date:  1984-06       Impact factor: 6.292

Review 5.  Flunarizine in migraine: a minireview.

Authors:  M Leone; L Grazzi; L La Mantia; G Bussone
Journal:  Headache       Date:  1991-06       Impact factor: 5.887

6.  Prophylactic treatment of migraine with tolfenamic acid. A comparative double-blind crossover study between tolfenamic acid and placebo.

Authors:  B M Mikkelsen; J V Falk
Journal:  Acta Neurol Scand       Date:  1982-07       Impact factor: 3.209

7.  CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges.

Authors:  K Nozaki; M A Moskowitz; P Boccalini
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

Review 8.  Dihydroergotamine: a review of its use in the treatment of migraine and other headaches.

Authors:  A K Scott
Journal:  Clin Neuropharmacol       Date:  1992-08       Impact factor: 1.592

Review 9.  Flunarizine. A reappraisal of its pharmacological properties and therapeutic use in neurological disorders.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

10.  Contingent negative variation and efficacy of beta-blocking agents in migraine.

Authors:  J Schoenen; A Maertens de Noordhout; M Timsit-Berthier; M Timsit
Journal:  Cephalalgia       Date:  1986-12       Impact factor: 6.292

View more
  2 in total

1.  Psychophysiologic Therapy for Chronic Headache in Primary Care.

Authors:  Angele V. McGrady; Frank Andrasik; Terrence Davies; Sebastian Striefel; Ian Wickramasekera; Steven M. Baskin; Donald B. Penzien; Gretchen Tietjen
Journal:  Prim Care Companion J Clin Psychiatry       Date:  1999-08

2.  Chiropractic management of a patient with migraine headache.

Authors:  Stacy Peters Harris
Journal:  J Chiropr Med       Date:  2005
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.